DualityBio Application Accepted for Breast Cancer Drug

DualityBio has announced that China's National Medical Products Administration (NMPA) has accepted its Biologics License Application (BLA). The application seeks approval for Trastuzumab Pamirtecan, a drug intended for the treatment of unresectable or metastatic HER2-positive adult breast cancer. This acceptance marks a significant milestone in the drug's development pathway, moving it closer to potential market availability in China. The company is focused on addressing unmet needs in oncology.